These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17568997)

  • 21. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies.
    Hu Z; Jin G; Wang L; Chen F; Wang X; Shen H
    Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2717-23. PubMed ID: 18086778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.
    Rihani A; Van Maerken T; De Wilde B; Zeka F; Laureys G; Norga K; Tonini GP; Coco S; Versteeg R; Noguera R; Schulte JH; Eggert A; Stallings RL; Speleman F; Vandesompele J
    Pediatr Blood Cancer; 2014 Oct; 61(10):1867-70. PubMed ID: 24391119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
    Walsh CS; Miller CW; Karlan BY; Koeffler HP
    Gynecol Oncol; 2007 Mar; 104(3):660-4. PubMed ID: 17123590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distribution and Effects of CDKN2 p16 540 C>G and 580 C>T, and MDM2 SNP309 T>G Polymorphisms in Patients with Primary Brain Tumors.
    Kafadar A; Küçükhüseyin Ö; Turan S; Yenilmez EN; Tunoglu S; Zeybek U; Kaynar MY; Kemerdere R; Yaylim I
    Anticancer Res; 2015 Jul; 35(7):3933-42. PubMed ID: 26124340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin.
    Wilkening S; Hemminki K; Rudnai P; Gurzau E; Koppova K; Försti A; Kumar R
    Br J Dermatol; 2007 Aug; 157(2):375-7. PubMed ID: 17553029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
    Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
    J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours.
    Dimitriadi M; Poulogiannis G; Liu L; Bäcklund LM; Pearson DM; Ichimura K; Collins VP
    Br J Cancer; 2008 Oct; 99(7):1144-52. PubMed ID: 18781178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do CDKN2 p16 540 C>G, CDKN2 p16 580 C>T, and MDM2 SNP309 T>G gene variants act on colorectal cancer development or progression?
    Tuna G; Küçükhüseyin O; Arıkan S; Kaytan Sağlam E; Güler E; Cacına C; Oztop O; Turan S; Korkmaz G; Yaylım I
    DNA Cell Biol; 2013 Jul; 32(7):400-8. PubMed ID: 23777425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation.
    Tu HF; Chen HW; Kao SY; Lin SC; Liu CJ; Chang KW
    Radiother Oncol; 2008 May; 87(2):243-52. PubMed ID: 18423915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore.
    Chua HW; Ng D; Choo S; Lum SS; Li H; Soh LY; Sabapathy K; Seow A
    BMC Cancer; 2010 Mar; 10():88. PubMed ID: 20219101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
    Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
    Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic potential of the MDM2 309T>G polymorphism in stage I lung adenocarcinoma.
    Enokida Y; Shimizu K; Atsumi J; Kakegawa S; Takase Y; Kaira K; Yashima H; Araki T; Nakazawa S; Ohtaki Y; Nagashima T; Alexander L; Usui K; Ishikawa T; Hayashizaki Y; Takeyoshi I
    Cancer Med; 2016 Aug; 5(8):1791-801. PubMed ID: 27228500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of MDM2 polymorphism: increased risk of developing colorectal cancer and a poor prognosis in the Tunisian population.
    Chaar I; Arfaoui TA; El Amine el HO; Mahmoud LB; Khiari M; Sammoud S; Lounis A; Amara S; Gharbi L; Hmida AB; Mzabi S; Bouraoui S
    Eur J Gastroenterol Hepatol; 2012 Mar; 24(3):320-7. PubMed ID: 22266832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma.
    Zhang JN; Yi SH; Zhang XH; Liu XY; Mao Q; Li SQ; Xiong WH; Qiu YM; Chen T; Ge JW
    Genet Mol Res; 2012 Oct; 11(4):3618-28. PubMed ID: 23096687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk.
    Petenkaya A; Bozkurt B; Akilli-Ozturk O; Kaya HS; Gur-Dedeoglu B; Yulug IG
    Anticancer Res; 2006; 26(6C):4975-7. PubMed ID: 17214373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset.
    Hamid S; Yang YH; Peng KN; Ismail SM; Zain RB; Lim KP; Wan Mustafa WM; Abraham MT; Teo SH; Cheong SC
    Oral Oncol; 2009 Jun; 45(6):496-500. PubMed ID: 18804411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genotypic interaction and gender specificity of common genetic variants in the p53/mdm2 network in Crohn's disease.
    Zimmer V; Widmann T; Müller M; Ong MF; Stein JM; Pfreundschuh M; Lammert F; Roemer K; Assmann G
    Digestion; 2010; 81(4):246-51. PubMed ID: 20110711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis.
    Wo X; Han D; Sun H; Liu Y; Meng X; Bai J; Chen F; Yu Y; Jin Y; Fu S
    J Genet Genomics; 2011 Aug; 38(8):341-50. PubMed ID: 21867960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
    Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
    Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.